These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 10877456)

  • 1. Epidemiology and pathogenesis of influenza.
    Zambon MC
    J Antimicrob Chemother; 1999 Nov; 44 Suppl B():3-9. PubMed ID: 10877456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zanamivir: a rational approach to influenza B.
    Penn CR; Osterhaus A
    Scand J Infect Dis; 2001; 33(1):33-40. PubMed ID: 11234975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of the role of neuraminidase in the receptor-binding activity of influenza B virus: the inhibitory effect of Zanamivir on haemadsorption.
    Luo C; Nobusawa E; Nakajima K
    J Gen Virol; 1999 Nov; 80 ( Pt 11)():2969-2976. PubMed ID: 10580059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
    Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
    Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathogenesis of influenza in humans.
    Zambon MC
    Rev Med Virol; 2001; 11(4):227-41. PubMed ID: 11479929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Flu' and structure-based drug design.
    Wade RC
    Structure; 1997 Sep; 5(9):1139-45. PubMed ID: 9331424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza virus neuraminidase inhibitors.
    Gubareva LV; Kaiser L; Hayden FG
    Lancet; 2000 Mar; 355(9206):827-35. PubMed ID: 10711940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
    Thompson CI; Barclay WS; Zambon MC
    J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular anatomy of 2009 influenza virus A (H1N1).
    Arias CF; Escalera-Zamudio M; Soto-Del Río Mde L; Cobián-Güemes AG; Isa P; López S
    Arch Med Res; 2009 Nov; 40(8):643-54. PubMed ID: 20304251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals.
    Leneva IA; Goloubeva O; Fenton RJ; Tisdale M; Webster RG
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1216-24. PubMed ID: 11257037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture.
    Baigent SJ; McCauley JW
    Virus Res; 2001 Nov; 79(1-2):177-85. PubMed ID: 11551658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Various sides of influenza, part I--structure, replication, changeability of influenza viruses, clinical course of the disease, immunological response and laboratory diagnostics].
    Machała MK; Brydak LB
    Pol Merkur Lekarski; 2006 Sep; 21(123):270-6. PubMed ID: 17163190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neuraminidase inhibitor].
    Kaji M
    Nihon Rinsho; 2000 Nov; 58(11):2293-8. PubMed ID: 11225320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
    Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
    J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuraminidase inhibitors for influenza.
    Moscona A
    N Engl J Med; 2005 Sep; 353(13):1363-73. PubMed ID: 16192481
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
    Hayden FG; Osterhaus AD; Treanor JJ; Fleming DM; Aoki FY; Nicholson KG; Bohnen AM; Hirst HM; Keene O; Wightman K
    N Engl J Med; 1997 Sep; 337(13):874-80. PubMed ID: 9302301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new antiviral agent for influenza--is there a clinical niche?
    Couch RB
    N Engl J Med; 1997 Sep; 337(13):927-8. PubMed ID: 9302309
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuraminidase inhibitors: zanamivir and oseltamivir.
    McNicholl IR; McNicholl JJ
    Ann Pharmacother; 2001 Jan; 35(1):57-70. PubMed ID: 11197587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zanamivir: from drug design to the clinic.
    Elliott M
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1885-93. PubMed ID: 11779388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.